A 65-year-old man presents to the urgent care clinic with a 1-day history of excruciating … — USMLE Step 3

A $65$ -year-old man presents to the urgent care clinic with a $1$ -day history of excruciating pain in his right big toe. The pain awoke him from sleep and is so severe that he cannot tolerate the weight of his bedsheets. His medical history is significant for ischemic cardiomyopathy with a left ventricular ejection fraction of $25\%$ , chronic kidney disease stage 4, type 2 diabetes mellitus, and hyperlipidemia. His current medications include carvedilol, sacubitril-valsartan, empagliflozin, furosemide, and atorvastatin. Vital signs show a blood pressure of $118/76$ mm Hg, heart rate of $72$ /min, and temperature of $37.1^\circ$ C. Physical examination reveals a markedly erythematous, swollen, and exquisitely tender right first metatarsophalangeal joint. The remainder of the joint examination is unremarkable. Laboratory studies from one week ago showed a serum creatinine of $2.6$ mg/dL (estimated glomerular filtration rate $24$ mL/min/ $1.73$ m $^2$ ) and a hemoglobin A1c of $7.8\%$ . Joint aspiration is deferred as the clinical presentation is highly classic for podagra. Which of the following is the most appropriate initial pharmacologic therapy for this patient's acute joint condition?

Intra-articular methylprednisoloneAnswer
B
Oral indomethacin
C
Oral colchicine
D
Oral allopurinol
E
Oral probenecid

Answer

Intra-articular methylprednisolone

The correct answer is intra-articular methylprednisolone. This patient has classic acute gouty arthritis (podagra). In a patient with multiple severe comorbidities including heart failure with reduced ejection fraction, stage 4 chronic kidney disease, and diabetes mellitus, systemic therapies pose significant risks. Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated due to heart failure and severe renal impairment. Colchicine is associated with severe neuromyopathy in advanced renal failure, a risk that is amplified by concomitant statin use. Systemic glucocorticoids could worsen both heart failure (through fluid retention) and diabetes (through hyperglycemia). Therefore, an intra-articular glucocorticoid injection provides rapid, effective, localized relief for monoarticular disease while safely circumventing the patient's systemic contraindications.

Step-by-Step Solution

Diagnose the acute condition.

The patient is experiencing an acute gout flare (podagra) of the first metatarsophalangeal joint.

The sudden onset of severe nocturnal pain, erythema, and exquisite tenderness at the first MTP joint is the classic presentation of acute gout.

Evaluate the patient's comorbidities and current medications.

The patient has HFrEF, Stage 4 CKD, Type 2 Diabetes, and takes a statin.

Comorbidities dictate which standard acute gout treatments (NSAIDs, colchicine, systemic steroids) are safe to use.

Eliminate contraindicated or high-risk systemic therapies.

NSAIDs and colchicine are ruled out. Systemic glucocorticoids are less desirable.

NSAIDs worsen CKD and HF. Colchicine causes toxicity in CKD, worsened by statins. Systemic steroids can exacerbate HF (fluid retention) and diabetes (hyperglycemia).

Select the safest effective intervention.

Intra-articular methylprednisolone is chosen.

For monoarticular gout, intra-articular glucocorticoids deliver potent anti-inflammatory effects directly to the joint while minimizing systemic absorption and avoiding systemic contraindications.

Key Concept

Management of acute gout flares in patients with multiple medical comorbidities that contraindicate standard systemic therapies.

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic